BUY VIDALISTA (CIALIS, TADALAFIL CITRATE) (60 MG/TAB. – 10 TABS)
MAIN PRODUCT DESCRIPTION
Product Overview
Vidalista 60 is an oral tadalafil-containing product identified in the supplied information as containing 60 mg of tadalafil per tablet. Tadalafil belongs to the pharmacological class known as phosphodiesterase type-5 (PDE-5) inhibitors and is used therapeutically in the management of erectile dysfunction (ED). Tadalafil is also used in certain formulations and doses for the signs and symptoms of benign prostatic hyperplasia (BPH).
The supplied product presentation contains 10 tablets. The source identifies Centurion Laboratories Pvt. Ltd. as the manufacturer. No independent regulatory documentation for this specific 60 mg presentation has been supplied.
Product Specifications
Product: Vidalista 60
Brand reference: Cialis / tadalafil
Active ingredient: Tadalafil
Strength: 60 mg per tablet
Dosage form: Tablet
Route: Oral
Pack size: 10 tablets
Pharmacological class: PDE-5 inhibitor
Manufacturer supplied: Centurion Laboratories Pvt. Ltd.
Regulatory status: Not independently verified for this presentation
Pharmacological Class and Mechanism
Tadalafil works through the nitric oxide–cyclic guanosine monophosphate (NO-cGMP) signalling pathway.
During sexual stimulation, nitric oxide is released in erectile tissue. This stimulates the formation of cGMP, a signalling molecule that promotes relaxation of smooth muscle and increases blood flow in the corpus cavernosum.
The PDE-5 enzyme normally breaks down cGMP. Tadalafil inhibits PDE-5 and therefore allows cGMP activity to persist for longer. This can support the physiological erectile response when sexual stimulation is present.
Tadalafil does not normally create sexual desire or cause an erection independently of stimulation. Its role is to facilitate the physiological mechanisms involved in erection.
Erectile Dysfunction
The supplied information describes Vidalista as a treatment for erectile dysfunction or sexual impotence.
Erectile dysfunction may have many underlying causes, including cardiovascular, metabolic, neurological, psychological and medication-related factors. A PDE-5 inhibitor addresses the erectile mechanism but does not necessarily treat the underlying cause of erectile dysfunction.
Persistent ED should therefore be medically evaluated rather than managed exclusively through repeated use of a PDE-5 inhibitor.
Duration of Action
The supplied source describes tadalafil as capable of supporting erectile function for a prolonged period, with an effect commonly described as lasting up to approximately 36 hours.
The duration of pharmacological activity should not be interpreted to mean that an erection persists throughout this period. Sexual stimulation remains necessary for the erectile response.
The exact onset and duration can vary between individuals and can be affected by other medicines, health conditions and food or alcohol intake.
Benign Prostatic Hyperplasia
Tadalafil is also used in appropriate formulations for the treatment of symptoms associated with benign prostatic hyperplasia (BPH).
Symptoms of BPH can include difficulty beginning urination, a weak urinary stream, urinary frequency and urgency, including increased nighttime urination.
Tadalafil’s effects on smooth muscle and vascular signalling can contribute to improvement of urinary symptoms in appropriately selected patients. Assessment should also consider other urological conditions that can cause similar symptoms.
Important Strength Consideration
The supplied presentation specifies 60 mg of tadalafil per tablet. This is higher than the commonly described as-needed tablet strengths in standard tadalafil prescribing information.
For this reason, the supplied 60 mg strength should be independently verified against the manufacturer’s packaging and applicable regulatory documentation before publication or dispensing.
The source’s statement that 60 mg is a “safe indicated dose” has not been reproduced as a recommendation. Patients should use only the strength and dose prescribed by a qualified healthcare professional.
Cardiovascular Safety
One of the most important safety issues associated with tadalafil is its interaction with organic nitrates.
Tadalafil can potentiate the blood-pressure-lowering effects of nitrates. Concomitant use is contraindicated because the resulting decrease in blood pressure can be severe and potentially life-threatening.
Patients taking medicines for angina or other nitrate-containing cardiovascular treatments must inform their healthcare professional before considering tadalafil.
Tadalafil should also be used cautiously with alpha-blockers and antihypertensive medicines, because additional blood-pressure lowering may occur.
Patients whose cardiovascular condition makes sexual activity inadvisable should receive appropriate medical evaluation before treatment.
Alcohol and Food
The supplied information advises caution with substantial alcohol consumption. Both tadalafil and alcohol can produce vasodilatory effects, and their combination may increase symptoms such as dizziness, headache, increased heart rate or a fall in standing blood pressure.
Tadalafil may generally be taken with or without food. However, patients should follow the instructions accompanying their specific product.
Adverse Reactions
The supplied information reports several possible adverse effects associated with tadalafil, including:
Headache
Nausea
Dizziness
Facial flushing
Digestive symptoms
Visual changes
Nasal congestion
Tadalafil is also associated with back pain and myalgia in some patients.
Patients should seek urgent medical attention for serious symptoms such as chest pain, severe allergic reactions, sudden vision loss, sudden hearing loss or an erection lasting longer than four hours.
Priapism
A prolonged erection lasting more than 4 hours requires urgent medical treatment. This condition, known as priapism, can cause permanent tissue damage if treatment is delayed.
Patients predisposed to priapism should receive appropriate medical advice before using tadalafil.
Visual and Hearing Warnings
Patients should discontinue tadalafil and seek prompt medical attention if they experience sudden loss or substantial reduction of vision.
Sudden hearing loss or a significant decrease in hearing also requires urgent medical evaluation.
These symptoms are uncommon but clinically important.
Drug Interactions
Tadalafil is predominantly metabolised by CYP3A4. Medicines that strongly inhibit CYP3A4 can increase tadalafil exposure.
The supplied information discusses potential interactions involving:
Ketoconazole
Ritonavir and other HIV protease inhibitors
Erythromycin
Itraconazole
Grapefruit products
Rifampin and other CYP3A4 inducers
Alpha-blockers
Antihypertensive medicines
Organic nitrates
The source also discusses interactions with medicines such as warfarin, aspirin and digoxin.
Patients should provide their healthcare professional with a complete list of prescription medicines, over-the-counter medicines, vitamins and supplements before using tadalafil.
Renal and Hepatic Considerations
Tadalafil exposure can increase in patients with impaired kidney function. The supplied information reports substantial increases in exposure in patients with reduced creatinine clearance and in those receiving haemodialysis.
Patients with liver impairment may also require special consideration because data for higher tadalafil doses and severe hepatic impairment are limited.
The 60 mg presentation should therefore not be used as a general dosing reference for patients with kidney or liver disease.
Dosage and Administration
The supplied source contains dosing instructions specific to the 60 mg product, including use before sexual activity. However, these instructions have not been reproduced as a recommended regimen.
Because the stated 60 mg strength requires verification, the appropriate dose must be determined according to the official prescribing information for the specific product and the patient’s clinical circumstances.
Do not increase the dose, repeat doses more frequently than prescribed or combine tadalafil with another PDE-5 inhibitor.
Sexual Health
Tadalafil can help with erectile function but does not protect against sexually transmitted infections, including HIV, hepatitis B, gonorrhoea or syphilis.
Appropriate sexual-health and barrier-protection measures remain necessary where applicable.
Manufacturer and Regulatory Information
The supplied source identifies Centurion Laboratories Pvt. Ltd. as the manufacturer.
No marketing authorisation number or independent regulatory verification for Vidalista 60, specifically at 60 mg per tablet, has been supplied. The product should therefore not be described as EU-authorised, prescription-free or legally available across all European countries without appropriate national regulatory verification.
The term “Cialis” should also be used carefully because Cialis is a specific tadalafil brand, while Vidalista is a separate product.
Important Pharmaceutical Disclaimer
Vidalista 60 contains a pharmacologically active PDE-5 inhibitor. The information supplied for this listing contains promotional statements concerning strength, performance, purchasing without prescription and dosing that have not been reproduced as established medical claims.
This product information is intended for general informational purposes and does not replace official prescribing information or professional medical advice. A qualified healthcare professional should determine whether tadalafil is appropriate and which dose is suitable.
